MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.
Journal of psychiatric research – May 01, 2022
Source: PubMed
Summary
Many individuals with severe PTSD also struggle with significant eating disorder symptoms, even without a formal diagnosis. Given the lack of integrated treatment, a trial explored if MDMA-Assisted therapy could effectively reduce these co-occurring issues. Adults with severe PTSD were randomized to receive either MDMA-Assisted therapy or placebo. Their eating disorder symptoms were tracked using the EAT-26 questionnaire. Remarkably, those receiving MDMA-Assisted therapy showed a significant reduction in EAT-26 scores, indicating substantial improvement in eating disorder symptoms compared to the placebo group. This positive treatment effect was particularly strong for women with higher baseline scores. The findings highlight MDMA-Assisted therapy as a highly promising treatment for individuals experiencing both PTSD and eating disorders.
Abstract
Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there are no proven integrative treatment modalities for ED-PTSD. In clinical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the treatment of PTSD and may be promising for ED-PTSD. Ninety individuals with severe PTSD received treatment in a double-blind, placebo-controlled pivotal trial of MDMA-AT. In addition to the primary (Clinician-Administered PTSD Scale) and secondary (Sheehan Disability Scale) outcome measures, the Eating Attitudes Test 26 (EAT-26) was administered for pre-specified exploratory purposes at baseline and at study termination. The study sample consisted of 58 females (placebo = 31, MDMA = 27) and 31 males (placebo = 12, MDMA = 19) (n = 89). Seven participants discontinued prior to study termination. At baseline, 13 (15%) of the 89 individuals with PTSD had total EAT-26 scores in the clinical range (≥20), and 28 (31.5%) had total EAT-26 scores in the high-risk range (≥11) despite the absence of active purging or low weight. In completers (n = 82), there was a significant reduction in total EAT-26 scores in the total group of PTSD participants following MDMA-AT versus placebo (p = .03). There were also significant reductions in total EAT-26 scores in women with high EAT-26 scores ≥11 and ≥ 20 following MDMA-AT versus placebo (p = .0012 and p = .0478, respectively). ED psychopathology is common in individuals with PTSD even in the absence of EDs with active purging and low weight. MDMA-AT significantly reduced ED symptoms compared to therapy with placebo among participants with severe PTSD. MDMA-AT for ED-PTSD appears promising and requires further study.